Drug-induced hyperthermia with rhabdomyolysis in CLN3 disease

被引:4
|
作者
Savvidou, A. [1 ,2 ]
Jennions, E. [1 ,2 ]
Wikstrom, S. [3 ,4 ]
Olsson-Engman, M. [5 ]
Sofou, K. [1 ,2 ]
Darin, N. [1 ,2 ]
机构
[1] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden
[2] Sahlgrens Univ Hosp, Dept Pediat, Reg Vastra Gotaland, Gothenburg, Sweden
[3] Cty Council Varmland, Ctr Clin Res & Educ, Varmland, Sweden
[4] Orebro Univ, Sch Med Sci, Orebro, Sweden
[5] Blekinge Hosp, Pediat Clin, Karlskrona, Sweden
关键词
Juvenile neuronal ceroid lipofuscinosis; CLN3; Neuroleptic malignant syndrome; Serotonin syndrome; Rhabdomyolysis; Neuroleptic malignant; NEUROLEPTIC MALIGNANT SYNDROME; SEROTONIN SYNDROME;
D O I
10.1016/j.ejpn.2022.06.007
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
CLN3 disease (MIM# 204200), the most prevalent of the neuronal ceroid lipofuscinoses (NCL), is an autosomal recessive disorder with juvenile onset characterized by blindness, epilepsy, dementia, psychiatric manifestations, and motor deterioration. Problems related to behavior, emotions and thought are among the main features. Antidepressant and antipsychotic drugs have been employed with variable results. Neuroleptic malignant syndrome (NMS) has previously been described in two patients with NCL, one with CLN3 disease and one with adult onset NCL of unclear genetic origin. Our aims were to describe the occurrence of drug-induced hyperthermia in pediatric patients with CLN3 disease from West and South Sweden and to delineate the range of associated clinical features. Our study identified four patients presenting with seven episodes of severe drug-induced hyperthermia and either NMS-like or Serotonin syndrome (SS)-like features. Possibly provoking drugs were risperidone, clozapine, olanzapine, haloperidol, quetiapine, and sertraline. The course was atypical, frequently prolonged, associated with rhabdomyolysis and status dystonicus, and resulted in the death of three of the patients. Our study points to a vulnerability to drug-induced hyperthermia in patients with CLN3 disease which we believe could be underreported. Interestingly the proposed pathophysiological mechanisms behind NMS and SS on one hand and CLN3 on the other hand seem to converge in a common mechanism involving dysregulation of the sympathetic nervous system.
引用
收藏
页码:74 / 78
页数:5
相关论文
共 50 条
  • [41] Disease progression in JNCL: Quantification and relation to CLN3 genotype
    Kwon, JM
    Rothberg, PG
    Marshall, FJ
    De Blieck, EA
    Adams, H
    Vierhile, A
    Stachowski, EK
    Pearce, DA
    Mink, JW
    NEUROLOGY, 2006, 66 (05) : 271 - 271
  • [42] Brain proton MR spectroscopy measurements in CLN3 disease
    Do, An N. Dang
    Baker, Eva H.
    Farmer, Cristan A.
    Soldatos, Ariane G.
    Thurm, Audrey E.
    Porter, Forbes D.
    MOLECULAR GENETICS AND METABOLISM, 2023, 139 (01)
  • [43] Autophagic vacuolar myopathy is a common feature of CLN3 disease
    Radke, Josefine
    Koll, Randi
    Gill, Esther
    Wiese, Lars
    Schulz, Angela
    Kohlschuetter, Alfried
    Schuelke, Markus
    Hagel, Christian
    Stenzel, Werner
    Goebel, Hans H.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2018, 5 (11): : 1385 - 1393
  • [44] Novel morphological macular findings in juvenile CLN3 disease
    Dulz, S.
    Wagenfeld, L.
    Nickel, M.
    Richard, G.
    Schwartz, R.
    Bartsch, U.
    Kohlschuetter, A.
    Schulz, A.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2016, 100 (06) : 824 - 828
  • [45] DRUG-INDUCED HYPERTHERMIA + AMPHETAMINE TOXICITY
    WOLF, HH
    GEORGE, DJ
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1964, 53 (07) : 748 - &
  • [46] Diagnosis and treatment of drug-induced hyperthermia
    Musselman, Megan E.
    Saely, Suprat
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (01) : 34 - 42
  • [47] Motor function impairment is an early sign of CLN3 disease
    Kuper, Willemijn F. E.
    van Alfen, Claudia
    van Eck, Linda
    Huijgen, Barbara C. H.
    Nieuwenhuis, Edward E. S.
    van Brussel, Marco
    van Hasselt, Peter M.
    NEUROLOGY, 2019, 93 (03) : E293 - E297
  • [48] Membrane topology of CLN3, the protein underlying Batten disease
    Mao, QW
    Foster, BJ
    Xia, HB
    Davidson, BL
    FEBS LETTERS, 2003, 541 (1-3) : 40 - 46
  • [49] The UBDRS predicts rate of JCNL (CLN3) disease progression
    Mink, Jonathan
    Kwon, Jennifer M.
    Marshall, Frederick J.
    Adams, Heather R.
    Rothberg, Paul G.
    deBlieck, Elisabeth A.
    Vierhile, Amy
    Newhouse, Nicole J.
    Levy, Erika J.
    Augustine, Erika F.
    Ramirez-Montealegre, Denia
    MOLECULAR GENETICS AND METABOLISM, 2010, 99 (02) : S27 - S27
  • [50] Evidence for phosphorylation of CLN3 protein associated with Batten disease
    Michalewski, MP
    Kaczmarski, W
    Golabek, AA
    Kida, E
    Kaczmarski, A
    Wisniewski, KE
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 253 (02) : 458 - 462